EGFR and breast carcinoma: It is noteworthy that MENA is a Wnt/β-catenin pathway target, since MENA is overexpressed in ∼75% of breast cancers and the Wnt/β-catenin pathway is overactivated in many breast cancer cell lines and tumors.